grepcent public filings, reorganized for comparison

VIBERZI — FDA application NDA206940

Application NDA206940 · type NDA · FDA status: approved · original approval 2015-05-27

Listed sponsor: ABBVIE · ABBV company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001VIBERZIELUXADOLINETABLETORAL75MGPrescriptionnot listedYes
002VIBERZIELUXADOLINETABLETORAL100MGPrescriptionnot listedYes

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

ListingProductDescriptive dateFlags/code
Patent 8691860001listed patent expiry date: 2028-07-07drug substance, U-1709
Patent 8691860002listed patent expiry date: 2028-07-07drug substance, U-1709
Patent 9115091001listed patent expiry date: 2028-07-07drug substance, drug product, U-1738
Patent 9115091002listed patent expiry date: 2028-07-07drug substance, drug product, U-1738
Patent 9364489001listed patent expiry date: 2028-07-07U-1709
Patent 9364489002listed patent expiry date: 2028-07-07U-1709
Patent 9789125001listed patent expiry date: 2028-07-07drug product, U-2152
Patent 9789125001listed patent expiry date: 2028-07-07drug product, U-1709
Patent 9789125002listed patent expiry date: 2028-07-07drug product, U-1709
Patent 9789125002listed patent expiry date: 2028-07-07drug product, U-2152
Patent 7741356001listed patent expiry date: 2029-05-27drug substance, drug product
Patent 7741356002listed patent expiry date: 2029-05-27drug substance, drug product
Patent 10188632001listed patent expiry date: 2033-03-14drug product
Patent 10188632002listed patent expiry date: 2033-03-14drug product
Patent 11007179001listed patent expiry date: 2033-03-14drug product
Patent 11007179002listed patent expiry date: 2033-03-14drug product
Patent 11090291001listed patent expiry date: 2033-03-14drug product
Patent 11090291002listed patent expiry date: 2033-03-14drug product
Patent 11160792001listed patent expiry date: 2033-03-14drug product
Patent 11160792002listed patent expiry date: 2033-03-14drug product
Patent 11229627001listed patent expiry date: 2033-03-14drug product
Patent 11229627002listed patent expiry date: 2033-03-14drug product
Patent 11311516001listed patent expiry date: 2033-03-14drug product
Patent 11311516002listed patent expiry date: 2033-03-14drug product
Patent 11484527002listed patent expiry date: 2033-03-14U-3475
Patent 12097187001listed patent expiry date: 2033-03-14U-3475
Patent 9675587001listed patent expiry date: 2033-03-14drug product
Patent 9675587002listed patent expiry date: 2033-03-14drug product
NDA206940 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA206940 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA206940 FDA listing datesDescriptive regulatory dates only; no relationship to revenue or future sales is stated or implied.Source: Drugs@FDA and FDA Orange Book.Listed dateDated listing marker0.001.002.002015-05-271.002028-07-071.002029-05-271.002033-03-141.00

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: Large-cap biopharma

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.